MetLife Investment Management’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

MetLife Investment Management’s Portfolio PAND Stock Details PAND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,066	Closed	-$304K	–	2530
2021 Q1	$304K	Buy	+5,066	New	+$183K	﹤0.01%	1806

MetLife Investment Management's PAND Position: Q2 2021 in Review

MetLife Investment Management sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q2 2021, closing a stake of 5,066 shares — an estimated $304K sold.

MetLife Investment Management first reported a position in PAND in Q1 2021 and held it in 1 quarter. The position peaked at $304K in Q1 2021. 0 funds tracked by Wall St. Rank hold PAND as of Q2 2021.

MetLife Investment Management reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
MetLife Investment Management sold 5,066 Pandion Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $304K.
MetLife Investment Management first reported a position in Pandion Therapeutics Inc. Common Stock in Q1 2021 and held it in 1 quarter.
MetLife Investment Management's Pandion Therapeutics Inc. Common Stock position peaked at $304K in Q1 2021.
0 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q2 2021.

Based on MetLife Investment Management's 13F filing for Q2 2021, filed 16 Aug 2021.